Cargando…
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
Acquired resistance to molecular targeted therapy is a significant challenge of the precision medicine era. The ability to understand these mechanisms of resistance may improve patient selection and allow for the development of rationally designed next-line or combination treatment strategies and im...
Autores principales: | Coleman, Niamh, Subbiah, Vivek, Pant, Shubham, Patel, Keyur, Roy-Chowdhuri, Sinchita, Yedururi, Sireesha, Johnson, Amber, Yap, Timothy A., Rodon, Jordi, Shaw, Kenna, Meric-Bernstam, Funda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636467/ https://www.ncbi.nlm.nih.gov/pubmed/34853384 http://dx.doi.org/10.1038/s41698-021-00240-w |
Ejemplares similares
-
Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015) -
Towards specific inhibition of mTORC2
por: Murray, Elizabeth R., et al.
Publicado: (2017) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo
por: Pan, Xiao-dong, et al.
Publicado: (2017) -
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)